Masimo (NASDAQ:MASI) Shares Up 3.1%

Masimo Co. (NASDAQ:MASI - Get Free Report) shares shot up 3.1% during trading on Tuesday . The stock traded as high as $115.68 and last traded at $114.80. 186,773 shares traded hands during trading, a decline of 71% from the average session volume of 645,020 shares. The stock had previously closed at $111.36.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on MASI. Piper Sandler boosted their price target on shares of Masimo from $160.00 to $165.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 7th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research note on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $144.67.

Masimo Price Performance

The firm has a market cap of $6.12 billion, a PE ratio of 78.37 and a beta of 0.98. The stock's fifty day moving average price is $114.51 and its 200-day moving average price is $125.90. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts' consensus estimates of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The business had revenue of $496.30 million for the quarter, compared to analyst estimates of $493.92 million. During the same quarter last year, the company earned $0.62 earnings per share. The business's revenue for the quarter was up 9.0% compared to the same quarter last year. As a group, equities analysts forecast that Masimo Co. will post 3.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Masimo

Large investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. raised its position in shares of Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 200 shares in the last quarter. Algert Global LLC bought a new stake in Masimo during the second quarter valued at $1,748,000. Deerfield Management Company L.P. Series C bought a new stake in Masimo during the second quarter valued at $233,000. Point72 Hong Kong Ltd acquired a new stake in shares of Masimo during the second quarter worth $3,183,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Masimo during the 2nd quarter valued at about $1,220,000. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.